Research Paper

Vitamin D: Multifaceted Roles in Health and Disease Pathophysiology

Yu Fu [1, 2], Juan Kong[1*]

[1]Department of Clinical Nutrition, Shengjing Hospital of China Medical University, Shenyang 110004, China,

[2]Department of Clinical Nutrition, The first people's hospital of Changzhou, Third affiliated hospital of Soochow university

***Correspondence to:** Juan Kong, **email:** kongj@cmu.edu.cn;

Received: November 13, 2024 **Accepted:** February 9, 2025 **Published:** February 21, 2025

ABSTRACT

This comprehensive review explores the expanding landscape of vitamin D research, highlighting its roles in immune modulation, carcinogenesis, metabolic regulation, and neuroprotection. Recent insights into genomic and non-genomic signaling pathways, epigenetic modifications, and tissue-specific bioavailability are discussed. Emerging therapeutic strategies involving vitamin D analogs and precision medicine approaches are evaluated, alongside unresolved controversies in clinical translation.

INTRODUCTION

Vitamin D, a fat-soluble secosteroid, exists in two bioactive forms: calcidiol (25-hydroxyvitamin D, denoted as 25(OH)D) and calcitriol (1,25-dihydroxyvitamin D, $1,25(OH)_2D$). Historically, its significance was primarily ascribed to the maintenance of calcium homeostasis and the promotion of skeletal integrity. However, contemporary investigations have unearthed a plethora of non-skeletal functions, implicating vitamin D in an array of physiological and pathophysiological processes.

The global prevalence of vitamin D insufficiency, defined as a serum 25(OH)D concentration of less than 30 ng/mL, is alarmingly high, affecting over 1 billion individuals across the globe. This high prevalence is attributable to multiple factors, including limited sun exposure due to indoor lifestyles, geographical location, skin pigmentation, and dietary habits. Given its widespread deficiency and broad spectrum of actions, vitamin D has emerged as a critical factor in public health research, with implications for chronic disease prevention and management [1].

MOLECULAR MECHANISMS OF ACTION

Genomic Pathways

The genomic actions of vitamin D are predominantly mediated by the vitamin D receptor (VDR), a member of the nuclear receptor superfamily. Once activated by $1,25(OH)_2D$, VDR heterodimerizes with the retinoid X receptor (RXR). This heterodimeric complex translocates to the nucleus and binds to specific DNA sequences known as vitamin D response elements (VDREs), typically located in the promoter or enhancer regions of target genes.

Recent advancements in chromatin immunoprecipitation sequencing (ChIP-seq) technology have enabled a comprehensive mapping of VDR-binding sites across the human genome. These studies have identified over 10,000 putative VDR-binding loci, many of which are situated in non-coding regions, suggesting potential roles in the regulation of long non-coding RNAs and microRNAs. Among the key pathways regulated by VDR are those involved in immune modulation, where genes encoding cytokines such as IL-1β, IL-10, and TNF-α are under its transcriptional control. In the context of cell cycle regulation, genes like CDKN1A (p21) and MYC are also influenced by VDR activation, thereby contributing to the control of cell proliferation, differentiation, and apoptosis [2, 3].

Furthermore, emerging evidence points towards the involvement of VDR in epigenetic remodeling. VDR can interact with histone deacetylases (HDACs) and histone acetyltransferases (HATs), enzymes that modify the chromatin structure by altering the acetylation status of histones. Such interactions can either promote or inhibit gene expression, depending on the specific context, adding an additional layer of complexity to the genomic actions of vitamin D [4].

Non-Genomic Signaling

In addition to the well-characterized genomic pathways, vitamin D also elicits rapid responses through non-genomic signaling mechanisms. These actions are mediated by membrane-bound VDR, which is distinct from the nuclear VDR.

Upon binding of $1,25(OH)_2D$ to the membrane VDR, a cascade of intracellular signaling events is initiated. One of the key pathways activated is the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Activation of this pathway has been shown to enhance macrophage phagocytosis, an essential process in the innate immune response against pathogens. Another important non-genomic signaling route involves the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway. Activation of this pathway has been implicated in the regulation of epithelial-mesenchymal transition (EMT), a process that is crucial during embryonic development but is also dysregulated in various pathological conditions, including cancer metastasis and tissue fibrosis [5, 6].

Moreover, vitamin D can modulate calcium homeostasis through non-genomic mechanisms. Activation of membrane VDR leads to the opening of transient receptor potential vanilloid 6 (TRPV6) calcium channels, resulting in a rapid influx of calcium ions into the cell. This calcium signaling is involved in a wide range of cellular functions, such as cell motility, secretion, and gene expression [7].

IMMUNE SYSTEM INTERACTIONS

Innate Immunity

Vitamin D plays a pivotal role in the modulation of innate immunity. Monocytes, upon exposure to $1,25(OH)_2D$, are primed to differentiate into M2 macrophages, which are characterized by their anti-inflammatory phenotype. These M2 macrophages secrete cytokines such as IL-10 and TGF-β, which are instrumental in dampening the inflammatory response and promoting tissue repair.

One of the most well-studied antimicrobial functions of vitamin D is the induction of cathelicidin (CAMP) and defensins. Cathelicidin is a cationic antimicrobial peptide that has broad-spectrum activity against bacteria, fungi, and viruses. In the context of tuberculosis, it has been demonstrated that $1,25(OH)_2D$ can enhance the production of cathelicidin in macrophages, thereby augmenting their ability to kill Mycobacterium tuberculosis. More recently, studies have also shown that vitamin D may play a role in the host defense against SARS-CoV-2, the virus responsible for COVID-19, by upregulating the expression of antimicrobial peptides and modulating the inflammatory response [8, 9].

CANCER BIOLOGY

Chemopreventive Effects

A substantial body of epidemiological evidence, including meta-analyses, has demonstrated an inverse association between circulating 25(OH)D levels and the risk of developing certain types of cancer. For instance, a comprehensive meta-analysis found that individuals with higher 25(OH)D levels had a significantly lower risk of colorectal cancer, with a hazard ratio of 0.72 (95% confidence interval: 0.61 - 0.85) [13].

The underlying mechanisms of the chemopreventive effects of vitamin D are multifaceted. In colon cancer, vitamin D has been shown to inhibit the Wnt/β-catenin signaling pathway, which is frequently dysregulated in this type of cancer. Activation of VDR by $1,25(OH)_2D$ leads to the upregulation of proteins that promote the degradation of β-catenin, thereby inhibiting the transcriptional activity of β-catenin and its downstream target genes involved in cell proliferation and survival [14].

In breast cancer, vitamin D can induce apoptosis through the activation of caspase-3, a key enzyme in the apoptotic pathway. Additionally, it can inhibit the growth and invasion of breast cancer cells by modulating the expression of genes involved in cell adhesion and extracellular matrix remodeling.

Another important aspect of the anti-cancer effects of vitamin D is its ability to suppress angiogenesis. By downregulating the expression of vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, vitamin D can limit the formation of new blood vessels that are essential for tumor growth and metastasis [15, 16].

Therapeutic Applications

The potential of vitamin D as an adjuvant therapy in cancer treatment has been investigated in several clinical trials. In advanced prostate cancer, phase III trials evaluating the use of calcitriol analogs, such as paricalcitol and maxacalcitol, in combination with chemotherapy have shown promising results. These studies reported an improvement in progression-free survival, suggesting that vitamin D analogs may enhance the efficacy of conventional cancer therapies [17].

However, the clinical use of vitamin D in cancer treatment is not without challenges. One of the major limitations is the development of dose-limiting hypercalcemia, which

can occur when high doses of vitamin D or its analogs are administered. This has led to the exploration of alternative strategies, such as the development of non-calcemic vitamin D analogs that can selectively target cancer cells without causing significant changes in calcium metabolism.

METABOLIC AND CARDIOVASCULAR HEALTH

Insulin Resistance

Insulin resistance, a hallmark of type 2 diabetes, is a complex disorder characterized by reduced responsiveness of target tissues, such as adipose tissue, skeletal muscle, and liver, to the action of insulin. Emerging evidence suggests that vitamin D may play a role in improving insulin sensitivity.In adipocytes, vitamin D can upregulate the expression and translocation of glucose transporter 4 (GLUT4), a key protein responsible for the uptake of glucose into cells. By enhancing GLUT4 function, vitamin D can increase glucose uptake and utilization in adipose tissue, thereby improving insulin sensitivity. Additionally, vitamin D has been shown to modulate the function of pancreatic β-cells, the cells responsible for insulin secretion. It can enhance insulin gene expression, insulin synthesis, and insulin secretion through its effects on calcium signaling pathways within β-cells [18, 19].

Recent studies have also implicated the gut microbiota in the relationship between vitamin D and insulin resistance. Vitamin D can influence the composition and function of the gut microbiota, and alterations in the gut microbiota have been associated with the development of insulin resistance. This suggests that the beneficial effects of vitamin D on insulin sensitivity may, in part, be mediated through its impact on the gut microbiota [20].

Cardiovascular Protection

The role of vitamin D in cardiovascular health has been the subject of extensive research. Vitamin D has been shown to have beneficial effects on endothelial function, which is crucial for maintaining vascular homeostasis. Endothelial cells line the inner surface of blood vessels and play a key role in regulating vasodilation, blood pressure, and the inflammatory response. Vitamin D can increase the bioavailability of nitric oxide (NO), a potent vasodilator, by upregulating the expression of endothelial nitric oxide synthase (eNOS). This leads to enhanced vasodilation and improved blood flow, thereby reducing the risk of cardiovascular diseases [21].

Furthermore, vitamin D can modulate the renin-angiotensin system (RAS), a key regulator of blood pressure. It has been demonstrated that $1,25(OH)_2D$ can suppress the transcription of the REN gene, which encodes renin, an enzyme that initiates the RAS cascade. By inhibiting renin production, vitamin D can reduce the activity of the RAS, leading to a decrease in blood pressure [22].

A meta-analysis of 18 randomized controlled trials (RCTs) evaluated the effect of vitamin D supplementation on blood pressure. The results showed that vitamin D supplementation was associated with a modest but significant reduction in systolic blood pressure, by approximately 3.3 mmHg, suggesting a potential role for vitamin D in the prevention and management of hypertension [23].

NEUROBIOLOGICAL ROLES

Neuroprotection

The presence of VDR in various regions of the brain, particularly in the hippocampus, suggests important roles for vitamin D in neuroprotection. In the context of Alzheimer's disease, one of the most prevalent neurodegenerative disorders, vitamin D has been implicated in reducing amyloid-β deposition. Amyloid-β is a peptide that aggregates to form plaques in the brains of Alzheimer's disease patients, and these plaques are thought to play a central role in the pathogenesis of the disease. Vitamin D can upregulate the expression of low-density lipoprotein receptor-related protein 1 (LRP1), which is involved in the clearance of amyloid-β from the brain. By enhancing LRP1

expression, vitamin D may promote the removal of amyloid-β plaques, thereby reducing their neurotoxic effects [24].

In Parkinson's disease, another neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, vitamin D has been shown to modulate mitochondrial function and α-synuclein aggregation. Mitochondrial dysfunction and abnormal aggregation of α-synuclein are key pathological features of Parkinson's disease. Vitamin D can enhance mitochondrial biogenesis and function, as well as reduce the aggregation of α-synuclein, potentially protecting dopaminergic neurons from degeneration [25].

Mental Health

Accumulating evidence suggests a link between vitamin D deficiency and mental health disorders, particularly depression. A meta-analysis of observational studies found a significant negative correlation between serum 25(OH)D levels and depression severity, with a correlation coefficient of -0.28 ($p < 0.01$). The proposed mechanisms underlying this association involve the regulation of the serotonergic pathway by vitamin D. Serotonin is a neurotransmitter that plays a crucial role in mood regulation, and alterations in serotonin function have been implicated in the pathogenesis of depression. Vitamin D can influence the synthesis, release, and reuptake of serotonin, thereby modulating mood. Additionally, vitamin D may also exert anti-inflammatory effects in the brain, as inflammation has been associated with the development of depression [26].

EMERGING THERAPEUTIC STRATEGIES

Selective VDR Agonists

In an effort to overcome the limitations associated with traditional vitamin D supplementation, such as the risk of hypercalcemia, the development of selective VDR agonists (SVDRAs) has emerged as a promising approach. SVDRAs are designed to selectively activate VDR in specific tissues or cell types, while minimizing off-target effects on calcium metabolism.

For example, eldecalcitol is a novel vitamin D analog that has been shown to have potent anti-osteoporotic effects with a relatively low risk of hypercalcemia. In preclinical and clinical studies, eldecalcitol has been demonstrated to increase bone mineral density and reduce the risk of fractures in postmenopausal women. Another example is tapinarof, a non-calcemic vitamin D receptor agonist that has shown promise in the treatment of psoriasis. Tapinarof can modulate the immune response in the skin without significantly affecting calcium homeostasis, offering a new therapeutic option for this chronic inflammatory skin disease [27].

Combination Therapies

Combination therapies involving vitamin D and other drugs have shown synergistic effects in various disease models. In the context of diabetes, studies have reported that the combination of vitamin D and metformin, a commonly used anti-diabetic drug, can enhance the activation of AMP-activated protein kinase (AMPK), a key regulator of energy metabolism. Activation of AMPK by this combination therapy leads to improved insulin sensitivity, increased glucose uptake, and enhanced fatty acid oxidation, suggesting a potential strategy for the more effective management of type 2 diabetes [28].

In cancer treatment, the combination of vitamin D and immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, has shown promise in preclinical and early-phase clinical trials. Vitamin D can modulate the tumor microenvironment by enhancing the infiltration and activation of T cells, thereby increasing the responsiveness of tumors to immune checkpoint blockade. This combination approach may offer a new therapeutic strategy for improving the efficacy of cancer immunotherapy [29].

Precision Medicine

Pharmacogenetic studies have identified several single nucleotide polymorphisms (SNPs) in genes involved in vitamin D metabolism and action that are associated with differential treatment responses. For example, SNPs in the CYP24A1 gene, which encodes an enzyme involved in the catabolism of vitamin D, such as rs6013897, have been shown to affect the serum levels of 25(OH)D and the response to vitamin D supplementation. Similarly, SNPs in the VDR gene, such as the FokI polymorphism, can influence the function of VDR and the transcriptional regulation of target genes. These genetic variations highlight the importance of personalized medicine approaches in optimizing vitamin D therapy. By taking into account an individual's genetic profile, healthcare providers can tailor vitamin D dosing and treatment strategies to maximize therapeutic efficacy and minimize adverse effects [30].

CONTROVERSIES AND CHALLENGES

Clinical Trial Discrepancies

Despite the promising preclinical and observational evidence supporting the beneficial effects of vitamin D, the results of large-scale clinical trials have been somewhat inconsistent. For example, the VITAL (Vitamin D and Omega-3 Trial) study, a large, randomized, placebo-controlled trial involving over 25,000 participants, reported no overall significant reduction in the risk of cardiovascular events with vitamin D supplementation. However, subgroup analyses of the VITAL study showed that individuals with baseline 25(OH)D levels less than 20 ng/mL may experience a reduced risk of cardiovascular disease with vitamin D supplementation. These findings highlight the complexity of the relationship between vitamin D and cardiovascular health and the importance of considering baseline vitamin D status and other individual factors when interpreting the results of clinical trials [31].

Biomarker Limitations

Current methods for measuring vitamin D status primarily rely on the quantification of total 25(OH)D in serum. However, this approach has several limitations. Only a small fraction of 25(OH)D in circulation is in the free, unbound form, which is thought to be the biologically active fraction. The majority of 25(OH)D is bound to vitamin D-binding protein (DBP) and albumin. Existing assays do not distinguish between free and protein-bound 25(OH)D, and thus may not accurately reflect the bioavailability of vitamin D. Additionally, factors such as genetic variations in D.

REFERENCES

[1] Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266 - 281.

[2] Teske K A , Yu O , Arnold L A .Inhibitors for the Vitamin D Receptor–Coregulator Interaction.Vitamins & Hormones, 2016, 100:45.

[3] Ramagopalan SV, et al. A ChIP - seq defined genome - wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010;20(10):1352 - 1360.

[4] Irfete S. Fetahu,Julia Höbaus,Enikő Kállay.Vitamin D and the epigenome.Frontiers in Physiology .2014;5:164

[5] Wang TT, et al. Cutting edge: 1,25 - dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(4):2909 - 2912.

[6] Wang F , Hu R , Zhang J ,et al.High-dose vitamin D3 c ameliorates renal fibrosis by vitamin D receptor activation and inhibiting TGF-β1/Smad3 signaling pathway in 5/6 nephrectomized rats[J].European Journal of Pharmacology, 2021:174271

[7] Peng JB, et al. Molecular cloning and characterization of a channel - like transporter mediating intestinal calcium absorption. J Biol Chem.

1999;274(44):31337 - 31342.

[8] Liu PT, et al. Toll - like receptor triggering of a vitamin D - mediated human antimicrobial response. Science. 2006;311(5768):1770 - 1773.

[9] Martineau AR, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta - analysis of individual participant data. BMJ. 2017;356:i6583.

[10]Kamen D L , Tangpricha V .Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity.Journal of Molecular Medicine, 2010, 88(5):441-450.

[11] Chen S , Sims G P , Chen X X ,et al.Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation.[J].Journal of Immunology, 2007,179(3):1634-47.

[12]Mao J , Yin H , Wang L ,et al.Prognostic value of 25-hydroxy vitamin D in extranodal NK/T cell lymphoma.Annals of Hematology, 2020(23):1-9.

[13] Giovannucci,Edward.The epidemiology of vitamin D and colorectal cancer: recent findings.Curr Opin Gastroenterol, 2006,22(1):24-29.

[14] Larriba, María,González-Sancho, José,Barbáchano, Antonio,et al.Vitamin D Is a Multilevel Repressor of Wnt/β-Catenin Signaling in Cancer Cells.Cancers, 2013, 5(4):1242-1260.

[15] Garland C F , Gorham E D , Mohr S B ,et al.Vitamin D and prevention of breast cancer: pooled analysis.[J].J Steroid Biochem Mol Biol, 2007, 103(3-5):708-711.

[16] Scher H I , Jia X , Chi K ,et al.Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with

castration-resistant prostate cancer.Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2011, 29(16):2191

[17] Zhao X Y , Feldman D .The role of vitamin D in prostate cancer.Steroids, 2001, 66(3-5):293-300.

[18] Pittas AG, et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta - analysis. J Clin Endocrinol Metab. 2007;92(6):2017 - 2029.

[19] Chiu KC, et al. Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am J Clin Nutr. 2004;79(5):820 - 825.

[20] Ross AC, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53 - 58.

[21] Shet S K , Gowdra A , Vishwanath H L ,et al.Serum Vitamin D Levels and Vascular Endothelial Growth Factor in Patients with Type 2 Diabetes Mellitus: A Cross-sectional Study.Journal of Clinical & Diagnostic Research, 2024, 18(3).

[22] Li YC, et al. 1,25 - Dihydroxyvitamin D3 is a negative endocrine regulator of the renin - angiotensin system. J Clin Invest. 2002;110(2):229 - 238.

[23] Witham MD, et al. Effect of vitamin D on blood pressure: a systematic review and meta - analysis. J Hypertens. 2009;27(4):746 - 755.

[24] Anindita B , Kumar K V , Anirban G ,et al.Vitamin D and Alzheimer's Disease: Neurocognition to Therapeutics.International Journal of Alzheimers Disease, 2015, 2015:192747.

[25] Detopoulou P , Voulgaridou G , Saridaki A ,et al.Vitamin D in Parkinson's disease: A systematic review of randomized controlled trials[J].Clinical Nutrition Open Science, 2023, 52:1-13

[26]Simon S .Vitamin D and Depression: A Systematic Review and Meta-Analysis Comparing Studies with and without Biological Flaws[J].Nutrients, 2014, 6(4):1501-1518.

[27] Yeung W G , Toussaint N D , Badve S V .Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence[J].Clinical Kidney Journal, 2024(8):8

[28]Mckenna M , Flynn M .Preventing Type 2 Diabetes With Vitamin D: Therapy Versus Supplementation[J].Annals of Internal Medicine, 2023, 176:415 - 416.

[29] Unger W W J , Laban S , Kleijwegt F S ,et al.Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.[J].European Journal of Immunology, 2010, 39(11):3147-3159

[30]Klena L , Galvankova K , Penesova A ,et al.Vitamin D supplementation in cancer prevention and the management of cancer therapy.Neoplasma, 2024, 71(4).

[31] Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380(1):33 - 44.